Clearmind Medicine announced that it has received final approval from Hadassah Medical Center to enroll patients in its Phase 1/2a clinical trial of CMND‑100 for alcohol use disorder. The trial, already active at Johns Hopkins University, Yale School of Medicine, and Tel Aviv Sourasky Medical Center, will now include the Israeli site under the leadership of Professor Joseph Caraco.
Adding Hadassah expands the trial’s recruitment capacity and broadens the diversity of the study population, which can accelerate the collection of safety, tolerability, pharmacokinetics, and preliminary efficacy data. A larger, more heterogeneous cohort strengthens the statistical power of the study and supports the generation of robust evidence needed for future regulatory submissions.
Clearmind’s financial profile remains modest. The company’s market capitalization is approximately $1.7 million, and it has received a Nasdaq notice for non‑compliance with the minimum stockholders’ equity requirement. Despite negative earnings per share and zero revenue growth, the company maintains a positive cash position relative to its debt, indicating a limited liquidity cushion for ongoing clinical development.
CEO Dr. Adi Zuloff‑Shani highlighted the completion of the first cohort as a key milestone, underscoring the company’s progress in demonstrating the clinical potential of CMND‑100. The expansion is positioned as a strategic step toward delivering a novel therapeutic option for a disorder that accounts for 4.7 % of global deaths and represents a multi‑billion‑dollar treatment market.
The AUD market is projected to grow from roughly $13.2 billion in 2024 to about $20 billion by 2032, creating a substantial commercial opportunity for effective therapies. Clearmind’s focus on a psychedelic‑derived compound aligns with emerging treatment paradigms and positions the company to capture a share of this expanding market.
With the new site approved, Clearmind will continue to enroll patients, collect data, and prepare for the next phases of clinical development. The company’s strategy emphasizes rapid data generation to support regulatory filings and eventual market entry, while navigating the financial and compliance challenges inherent to a clinical‑stage biotech.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.